When will the therapy be available for patients?

The clinical trial presented above is part of the TherVacB EU project. It is the first step to test the safety and efficacy of the therapy in people with chronic hepatitis B. If this trial is successful, further clinical trials (phase II and III) will follow to complete the clinical development. This is routinely required for new medical treatments before they can be approved for standard and regular use.
If these trials are successful, TherVacB could become the first vaccine to achieve a functional cure for hepatitis B.